Selumetinib in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia

NCT00588809 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

47

Enrollment

NIH

Sponsor class

Conditions

Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)
Adult Acute Promyelocytic Leukemia (M3)
Myelodysplastic Syndromes
Myelodysplastic/Myeloproliferative Neoplasms
Recurrent Adult Acute Myeloid Leukemia
Secondary Acute Myeloid Leukemia

Interventions

DRUG: selumetinib

Sponsor

National Cancer Institute (NCI)